Please assess the completion status of the following clinical trial:

Trial Title: Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed cutaneous malignant melanoma~  * Recurrent or metastatic disease that is not curable by surgical or other means~* Clinically and/or radiologically documented disease defined as at least one site of disease unidimensionally measurable ≥ 20 mm by x-ray, physical exam, or nonspiral CT scan OR ≥ 10 mm by spiral CT scan~* Must have nonbulky metastatic disease defined as the largest measurable lesion ≤ 50 mm in maximum diameter~* Must have primary diagnosis tumor tissue or previously resected metastatic melanoma tissue available (i.e., paraffin block or unstained slides)~* No known brain metastases~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy ≥ 12 weeks~* Absolute granulocytes count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Bilirubin normal~* Serum creatinine ≤ 1.5 times upper limit of normal (ULN)~* AST and ALT ≤ 2.5 times ULN~* Negative pregnancy test~* Not pregnant or nursing~* Fertile patients must use effective contraception during study therapy~* No uncontrolled intercurrent illness or condition including, but not limited to, any of the following:~  * Ongoing or active infection~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~ * Psychiatric illness or social situation that would limit compliance with study requirements~* No history of hemolysis or a hemolytic disorder including, but not limited to, any of the following:~  * Sickle cell anemia~ * Thalassemia~ * Autoimmune hemolytic anemia~* No history of other malignancies within the past 5 years except adequately treated nonmelanoma skin cancer, curatively treated carcinoma in situ of the cervix, or other solid tumors curatively treated with no evidence of disease~* No known HIV, hepatitis B, or hepatitis C infection~* Patients must reside within a 2-hour drive from a participating center~PRIOR CONCURRENT THERAPY:~* No previous systemic therapy for metastatic disease~* At least 3 months since prior adjuvant immunotherapy for recurrent melanoma~  * No prior immunotherapy for metastatic disease~ * No prior immunotherapy outside the adjuvant setting~* At least 4 weeks since prior major surgery~* At least 4 weeks since prior radiotherapy except low-dose, nonmyelosuppressive radiotherapy and recovered~* More than 4 weeks since prior and no concurrent investigational agents or anticancer therapy~* No prior chemotherapy including regional therapy~* No concurrent systemic corticosteroids (e.g., prednisone or dexamethasone)~  * Concurrent topical steroids are allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Recombinant human interleukin-21 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete